CLNN

+ Watchlist + Portfolio

Clene Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.08
52-Week Range: $3.25 – $13.50
Market Cap: $55.58M
P/E (TTM): —
EPS (TTM): -3.52
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -56.88%
Gross Margin: 70.05%
Operating Margin: -5941.11%
Profit Margin: 0.00%
Current Ratio: 3.07
Debt/Equity: —
Total Debt: $22.34M
Free Cash Flow: $-9.87M
Revenue Growth: 233.30%
Earnings Growth: —
Enterprise Value: $62.91M

CLNN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$473.00K	$654.00K	$342.00K	$200.00K
Cost of Revenue	$26.00K	$121.00K	$70.00K	$43.00K
Gross Profit	$447.00K	$533.00K	$272.00K	$157.00K
Research & Development	$31.92M	$26.66M	$20.06M	$14.01M
Selling, General & Admin	$16.16M	$12.83M	$12.43M	$8.43M
Operating Expenses	$45.00M	$38.79M	$32.25M	$21.97M
Operating Income	-$44.56M	-$38.26M	-$31.98M	-$21.82M
EBITDA	-$25.60M	-$43.24M	-$33.69M	-$22.00M
Pretax Income	-$29.92M	-$49.50M	-$39.40M	-$26.17M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$29.92M	-$49.50M	-$39.40M	-$26.17M
Diluted EPS	-9.20	-9.43	-5.67	-2.65
Diluted Shares	3.26M	5.25M	6.95M	9.86M

CLNN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$18.33M	$28.82M	$12.15M	$5.19M
Receivables	$2.97M	$1.34M	$391.00K	$590.00K
Inventory	$43.00K	$37.00K	$68.00K	$37.00K
Current Assets	$29.20M	$38.85M	$16.16M	$8.98M
Total Assets	$44.49M	$52.34M	$27.34M	$18.13M
Current Liabilities	$13.86M	$25.33M	$10.29M	$10.78M
Long-Term Debt	$19.25M	$7.15M	$15.43M	$13.54M
Total Debt	$31.82M	$32.16M	$20.84M	$21.67M
Total Liabilities	$41.26M	$38.95M	$36.19M	$35.72M
Retained Earnings	-$193.22M	-$242.72M	-$282.12M	-$308.30M
Shareholders' Equity	$3.24M	$13.39M	-$8.86M	-$17.59M
Working Capital	$15.34M	$13.52M	$5.87M	-$1.80M
Net Debt	$7.34M	—	$3.63M	$12.43M

CLNN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$39.01M	-$30.17M	-$21.33M	-$18.55M
Capital Expenditure	-$5.18M	-$330.00K	-$15.00K	-$39.00K
Free Cash Flow	-$44.19M	-$30.50M	-$21.34M	-$18.59M
Depreciation & Amortisation	$1.02M	$1.71M	$1.65M	$1.50M
Stock-Based Compensation	$8.51M	$9.12M	$7.95M	$6.38M
Investing Cash Flow	-$10.16M	-$1.50M	$6.32M	-$39.00K
Financing Cash Flow	$17.25M	$42.16M	-$1.53M	$11.52M
Net Change in Cash	-$31.93M	$10.49M	-$16.54M	-$7.07M

CLNN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$81.00K	$27.00K	$15.00K	$77.00K	$15.00K	$90.00K
Cost of Revenue	$20.00K	$0.00	$0.00	$23.00K	$0.00	$36.00K
Gross Profit	$61.00K	$27.00K	$15.00K	$54.00K	$15.00K	$54.00K
Research & Development	$1.48M	$3.51M	$3.51M	$5.50M	$329.00K	$3.47M
Selling, General & Admin	$2.44M	$2.19M	$1.98M	$1.81M	$1.63M	$1.85M
Operating Expenses	$3.63M	$5.66M	$5.39M	$7.30M	$1.71M	$5.22M
Operating Income	-$3.57M	-$5.63M	-$5.37M	-$7.24M	-$1.69M	-$5.16M
EBITDA	$261.00K	-$6.37M	-$7.76M	-$8.12M	-$6.95M	-$12.38M
Pretax Income	-$751.00K	-$7.42M	-$8.78M	-$9.23M	-$8.09M	-$13.42M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$751.00K	-$7.42M	-$8.78M	-$9.23M	-$8.09M	-$13.42M
Diluted EPS	-0.09	-0.78	-0.85	—	-0.69	-1.08
Diluted Shares	8.82M	9.52M	10.28M	—	11.64M	12.38M

CLNN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$9.83M	$7.29M	$7.92M	$5.19M	$5.94M	$9.67M
Receivables	$1.51M	$1.32M	$550.00K	$590.00K	$3.51M	$1.18M
Inventory	$38.00K	$79.00K	$61.00K	$37.00K	$54.00K	$37.00K
Current Assets	$14.67M	$11.98M	$12.67M	$8.98M	$13.02M	$14.91M
Total Assets	$25.31M	$22.13M	$22.31M	$18.13M	$21.66M	$23.04M
Current Liabilities	$10.76M	$7.57M	$8.31M	$10.78M	$6.73M	$4.85M
Long-Term Debt	$12.91M	$15.75M	$15.79M	$13.54M	$16.34M	$18.31M
Total Debt	$20.94M	$20.85M	$21.31M	$21.67M	$22.05M	$22.34M
Total Liabilities	$30.29M	$30.68M	$34.67M	$35.72M	$40.47M	$47.82M
Retained Earnings	-$282.87M	-$290.29M	-$299.07M	-$308.30M	-$316.39M	-$329.81M
Shareholders' Equity	-$4.97M	-$8.55M	-$12.36M	-$17.59M	-$18.81M	-$24.78M
Working Capital	$3.91M	$4.41M	$4.37M	-$1.80M	$6.29M	$10.06M
Net Debt	$6.20M	$8.84M	$9.12M	$12.43M	$12.27M	$9.05M

CLNN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$5.01M	-$4.74M	-$3.99M	-$4.80M	-$4.53M	-$2.59M
Capital Expenditure	—	—	—	-$28.00K	—	—
Free Cash Flow	-$5.01M	-$4.74M	-$4.00M	-$4.83M	-$4.53M	-$2.59M
Depreciation & Amortisation	$404.00K	$366.00K	$365.00K	$360.00K	$355.00K	$353.00K
Stock-Based Compensation	$1.95M	$1.37M	$1.70M	$1.36M	$1.31M	$1.04M
Investing Cash Flow	$0.00	$0.00	-$11.00K	-$28.00K	$0.00	-$1.00K
Financing Cash Flow	$2.67M	$2.13M	$4.64M	$2.07M	$5.23M	$6.33M
Net Change in Cash	-$2.34M	-$2.61M	$639.00K	-$2.76M	$706.00K	$3.74M

Market Snapshot

About

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotechnology-based therapeutics for neurodegenerative diseases. Based in Salt Lake City, Utah, the company's lead asset is CNM-Au8, a suspension of gold nanocrystals designed to improve cellular energetics and neuroprotection. Clene is advancing CNM-Au8 in clinical trials for amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease, targeting mitochondrial dysfunction underlying these conditions. The company's nanomedicine platform aims to deliver therapeutic benefits through catalytic mechanisms rather than traditional pharmacology.